Immunic, Inc. Reveals 2025 Financial Outcomes and Strategic Plans

Immunic, Inc., a leader in biotechnology, shared its financial results for 2025 and provided updates on its strategic initiatives. The company anticipates releasing top-line data from the Phase 3 ENSURE trials for vidofludimus calcium in relapsing multiple sclerosis by late 2026. Immunic secured $200 million in private investment, with the potential for an additional $200 million, to fund key projects.

The funds will support the completion of the ENSURE trials, initiation of a Phase 3 trial in primary progressive multiple sclerosis, and their transition into a commercial entity. CEO Daniel Vitt emphasized the importance of this financing milestone in advancing their multiple sclerosis program.

Immunic reported a net loss of $97.2 million for 2025, slightly less than the previous year. The company holds $15.5 million in cash, with expectations to sustain operations into late 2027, following additional fundraising efforts.